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Evaluation of FHIT gene alterations in ovarian cancer
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Summary The FHIT gene, recently cloned and mapped on chromosome 3p14.2, has frequently been found to be abnormal in several
established cancer cell lines and primary tumours. As alterations of chromosome 3p are common events in ovarian cancers with breakpoint
sites at 3p14.2, we decided to investigate the role of FHIT in human ovarian tumorigenesis. Fifty-four primary ovarian carcinomas were
studied by reverse transcription of FHITmRNA followed by polymerase chain reaction (PCR) amplification and sequencing of products. The
same tumours and matched normal tissues were also investigated for loss of heterozygosity using three microsatellite markers located inside
the gene. We found an abnormal transcript of the FHITgene in two cases (4%) and allelic losses in eight cases (15%). Twelve (22%) of the
54 tumours investigated belonged to young patients with afamily history of breast/ovarian cancer. In none of these cases was the FH/Tgene
found to be altered. Our results indicate that FH/Tplays a role in a small proportion of ovarian carcinomas.
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Ovarian cancer represents the most frequent cause of death for
gynaecological malignancies in the Western world (Shelling et al,
1995). In fact, after primary surgery, the overall 5-year survival is
still very low, mainly because of lack of improvement in early
diagnosis andparticular aggressiveness ofthe disease (Chang etal,
1994). As the genetic background of neoplastic cells may deter-
mine theirbiological behaviour, several studies have been focused
on the analysis of genomic loci subjected to allelic losses on
different chromosomes to identify potential tumour-suppressor
genes in ovarian cancer (Eccles et al, 1990; Russel et al, 1990;
Cliby etal, 1993; Osborne andLeech, 1994). Complex cytogenetic
abnormalities have been demonstrated in ovarian carcinomas;
some ofthem seem to be non-random (Islam et al, 1993; Jenkins et
al, 1993), including loss ofheterozygosity (LOH) at chromosome
3p (Ehlen and Dubeau, 1990; Zheng et al, 1991; Leary et al, 1993).
Recently, the FHIT gene has been identified by an exon-trapping
strategy in cancer cell lines with homozygous deletions at region
3pl4.2 (Kastury et al, 1996). FHIT is a highly conserved gene
composed of ten exons distributed over approximately 1 Mb of
genomic DNA, with three untranslated exons. This gene encom-
passes the FRA3B, an aphidicolin inducible fragile site and the site
of t(3;8) translocation breakpoint of familiar renal cell carcinoma
(Ohta et al, 1996). The FHIT protein shows a high homology to
the yeast Schizosaccharomyces pombe diadenosine tetraphosphate
hydrolase (Huang et al, 1995). This similarity suggests that the
FHIT protein may have hydrolase activity and might cleave
the diadenosine 5',5"-P',P4-tetraphosphate (Ap4A), a molecule
involved in DNA replication and cell cycle control (Barnes et al,
1996). It has also been demonstrated that the introduction ofchro-
mosome 3pl4-p12 into renal carcinoma cells with a t(3;8) translo-
cation in that region resulted in partial suppression of tumour
growth (Sanchez et al, 1994). These data strongly suggest that the
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FHIT gene is a putative tumour suppressor. Abnormalities of the
FHIT locus were found in several established cancer cell lines
and in primary resected tumours, including lung, breast, oesoph-
agus, stomach and pancreas carcinomas (Kastury et al, 1996;
Negrini et al, 1996; Shridhar et al, 1996; Sozzi et al, 1996a and b;
Thiagalingam et al, 1996).
In the current study, we have investigated the FHIT gene for
deletions within the locus and for the presence of abnormal tran-
scripts in a series of54 ovarianepithelial malignanciescomprising
42 carcinomas developed in post-menopausal patients (mean age
58 years) and 12 tumours developed in young patients (mean age
33 years) with afamily history ofbreast ovarian cancer.
MATERIAL AND METHODS
Patients
Fifty-four patients with invasive ovarian carcinoma were studied.
Tumour samples and matching normal ovarian tissues were
collected during the surgical procedure, snap frozen in liquid
nitrogen within 10 min ofexcision and stored at -80°C.
To avoid contamination of neoplastic cells with normal tissue,
the proportion of tumour cells in frozen neoplastic samples was
evaluated on frozen cryostat sections and, in some cases, micro-
dissection of specimens was performed to assure a maximum
percentage of tumour in each sample before DNA and RNA
extraction. Immediately, adjacent pieces of tumour tissue were
formalin fixed and processed for diagnostic histopathology. The
tumours were histologically typed and graded according to the
World Health Organization (Serov et al, 1973). Tumour stage was
determined according to the criteriaofthe International Federation
of Gynaecology and Obstetrics (FIGO) (Beahrs et al, 1988); 15
patients had stage I-II disease and 39 patients had stage III-IV
disease. With respect to grade of neoplastic differentiation, 12
carcinomas were well differentiated (grade 1), 15 moderately
differentiated (grade 2) and 27 poorly differentiated (grade 3). Of
the patients included in this study, 12 were under 45 years old and
showed a family history ofbreast ovarian cancer.
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Figure 1 Detection of FHlTtranscripts by RT-PCR of ovarian tumour
mRNAs. All of the samples showed a normally sized product, which is
missing in tumour no. 48. In tumours no. 39 and no. 48, a smaller band,
corresponding to an altered FHlTtranscript, was seen
Table 1 Analysis of the FHITlocus in ovarian cancer
Cases RT-PCRa Sequenceb LOH
12 N Yes
39 N Yes
A Deletion of exons 5 and 6 (nt -17-249)
41 N Yes
45 N Yes
48 A Deletion of exon 5-8 (nt -17-348) Yes
50 N Yes
52 N Yes
76 N Yes
aN, normal; A, altered. bnt, nucleotide.
Allelic losses analysis
DNAs from frozen tumours and matching normal tissues were
extracted using standard protocols (Sambrook et al, 1989).
Analysis of allelic losses of the FHIT gene was performed on
tumours and matching normal ovarian tissues using a polymerase
chain reaction (PCR)-based method using, for each case, three
microsatellite markers (D3S4103, D3S1300 and D3S1234)
(Kastury et al, 1996; Ohta et al, 1996), all internal to the FHIT
gene. D3S1300 and D3S4103 markers are located in the epicentre
of the fragile region encompassing exon 5 of the FHIT gene and
D3S1234 is located distally in the intron 8, at the 3' end of the
gene. An additional microsatellite marker, D3S1271, located at
chromosomal band 3p1.2 was used as control for LOH outside
the FHITgene. The sequences ofall primers used can be obtained
through the genome database. Routinely, 100 ng ofgenomic DNA
was used in a 10-gl PCR reaction containing 10 mM Tris-HCI
(pH 8.3), 1.5 mm magnesium chloride, 50 mM potassium chloride,
0.01% (w/v) gelatine, 1.25 mm each of four dNTPs (Boehringer
Mannheim Biochemica), 1 mm of each primer, 0.5,l of [a-
32P]dCTP (3000 Ci mmol-', Amersham, Arlington, IL, USA) and
0.25 units ofTaq DNA polymerase (Perkin-Elmer Cetus, Norwalk,
CT, USA). The PCR reaction was programmed as follows: initial
denaturation, 5 min at 94'C; amplification, 30 s at 94°C, 30 s at
57-60°C, 30 s at 72°C for 20 cycles; elongation, 10 min at 72°C.
PCR products were processed by the addition of 5 tl of loading
buffer consisting of 98% formamide, 1% EDTA (pH 8.0), 0.03%
xylene cyanol and 0.03% bromophenol blue. The reaction was
denatured at 95°C for 5 min. An aliquot of 5 ,l was loaded onto a
6% urea-polyacrylamide gel for 2-3 h at 55 W. The gels were
dried and exposed against a Kodak XAR-5 film at -80°C. For
informative cases, allelic loss was scored if the autoradiographic
signal ofone allele was approximately 50% reduced in the tumour
DNA compared with the corresponding normal allele.
Reverse transcription polymerase chain reaction
(RT-PCR) and cDNA sequence analysis of
tumour-derived mRNA
Total mRNA was extracted from 54 frozen tumours and corre-
sponding normal tissues using the Tri Reagent kit (Molecular
Research Centre, INC-Bioptica). First-strand cDNA was synthe-
sized from 1 ,ug oftotal RNA. The reaction was performed in a 30-
,l final volume of 50 mm Tris-HCl (pH 8.3), 75 mm potassium
chloride, 3 mm magnesium chloride, 10 mm DTT, 2 mM dNTPs,
500 ng ofoligo (dT), 600 units ofMMLV-RT (Clontech), 40 units
of RNasin (Clontech) and 1 ,ug of RNA. The samples were incu-
bated at 420C for 1 h and then boiled for 5 min to stop the cDNA
synthesis reaction and to destroy any DNAase activity.
PCR amplification was performed, starting from 1 ,l ofcDNA,
in 25 ,l containing 10 mm Tris-HCI (pH 8.3), 0.8 ,UM of primers
SU1 and 3D1 (Ohta et al, 1996), 50 mm of each dNTP, 50 mm
potassium chloride, 0.1 mg ml' gelatin, 15 mm magnesium
chloride and 2.5 units of Taq polymerase (Boehringer Mannheim
Biochemica). The PCR reaction was programmed as follows:
initialdenaturation, 3 min at94°C; amplification, 15 s at 940C, 30 s
at 62°C, 45 s at 72°C for 30 cycles; elongation, 10 min at 72°C.
The PCR products were resolved on 2.5% ethidium bromide-
stained gel. Bands were cut from the gel and, after purification,
70-80 ng ofcDNA were sequenced using primers 5U2 and 3D2 by
the dideoxynucleotide termination reaction chemistry for sequence
analysis (T7 Sequenase vers. 2; Amersham, Life Science).
RESULTS
To investigate the presence of abnormal transcripts of the FHIT
gene, we reverse transcribed mRNAs and amplified the resulting
cDNAs from 54 tumours and corresponding normal tissues. In all
but one (case no. 48) of the tumour DNAs, the RT-PCR analysis
revealed a band ofthe same size, corresponding to a normal-sized
transcript (Figure 1). In tumour no. 48 and in one other neoplastic
sample (case no. 39), with a normally sized message, a smaller
band, presumably corresponding to an altered transcript, was seen
(Figure 1). In these two cases, the matched non-neoplastic tissues
showed only the normal FHITmessage.
Sequence analysis of the major RT-PCR product was
performed. The results revealed a full-length size FHITtranscript.
Sequence analysis ofabnormally sized transcripts showed a loss of
exons 5-8 (nucleotides -17-348) in tumour no. 48 and a loss of
exons 5 and 6 (nucleotides -17-249) in tumour no. 39 (Table 1).
Therefore, based on RT-PCR analysis, only 4% (2 of 54) of the
ovarian carcinomas showed a FHITalteration.
The same tumours and matched normal tissues were also inves-
tigated for LOH at D3S1300, D3S4103 and D3S1234 micro-
satellite-containing loci. The normal tissues of all samples were
heterozygous for at least one ofthese markers.
We found LOH affecting at least one locus in 7 of 54 (13%)
ovarian carcinomas (Figures 2 and 3). These seven cases included
one of the two tumours showing an abnormal transcript (case no.
39). Tumour DNA from sample no. 48 was not amplifiable with
any of the couples of primers for microsatellite-containing sites
located within the FHIT gene, indicating a homozygous deletion
of the FHIT locus (data not shown). In order to demonstrate that
the results obtained for tumour sample no. 48 were not because of
quality ofDNA, the same sample was subjected to PCR amplifica-
tion of exon 5 of the p53 gene as previously described (Marchetti
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Figure 2 Allelic losses at D3S1300 locus. Primers specific for the
microsatellite D3S1300 were used to amplify genomic DNA obtained from
ovarian carcinomas
et al, 1993). An expected 290-bp p53 fragment was amplifiable,
supporting the conjecture that tumour no. 48 does indeed have a
deletion in the FHITgene.
All of the seven ovarian carcinomas showing allelic losses of
the FHIT gene were informative for locus D3S1271 and retained
the constitutional heterozygosity.
Both tumours showing an abnormal transcript of the FHIT gene
(cases no. 48 and no. 39) were ofhigh histological grade (G3) and
belonged to patients with advanced (III-IV) stage ofdisease. Ofthe
seven tumours with LOH (including case no. 39), one was of low
histological grade (GI), two showed a moderate histological differ-
entiation (G2) and four were ofhigh histological grade (G3). These
seven cases included two tumours obtained from patients at low
stages (I-II) of disease and five tumours from patients at advanced
stages (III-IV). Taken together, these results suggest that FHIT
alterations may be more frequent in tumours with higher histo-
logical grade and clinical stage. However, the number of cases
with FHITaberrations is too low to draw definitive conclusions.
DISCUSSION
It has been assumed that ovarian cancer, as well as other neoplastic
diseases, develops and progresses after the accumulation of a crit-
ical number of mutations within regulatory genes (Shelling et al,
1995). With the exception of the p53 gene, which is mutated in
most of the aggressive ovarian carcinomas (Bosari et al, 1993;
Kupryjancyk et al, 1993; Buttitta et al, 1997), other tumour-
suppressor genes and oncogenes are infrequently altered in ovarian
neoplasms.
It is known that the majority ofepithelial ovarian cancers appear
to be aneuploid and contain a variety of structural chromosomal
abnormalities (Dodson et al, 1993; Islam et al, 1993; Shelling et al,
1995), including LOH at many loci that could contain tumour-
suppressor genes (Thompson et al, 1994). Several studies have
demonstrated allelic losses at chromosome 3p in different human
carcinomas, including ovarian cancer (Ehlen and Dubeau, 1990;
Zheng et al, 1991; Jones and Nakamura, 1992; Leary et al, 1993).
The putative tumour-suppressor FHIT gene has been recently
cloned and localized on the short arm of chromosome 3. Recent
data have shown FHIT gene abnormalities in a variety of cancer-
derived cell lines, as well as in primary tumours. In particular,
aberrant transcripts ofthe FHITlocus were found in 80% ofsmall-
cell lung cancers (Sozzi et al, 1996a) and in 40% ofnon-small-cell
lung cancers (Sozzi et al, 1996a), in 50% of oesophageal and
stomach tumours and in 30% of breast carcinomas (Negrini et al,
1996). Discordant results have been reported in colorectal tumours
(Ohta et al, 1996; Thiagalingam et al, 1996).
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Figure 3 Microsatellite analysis of seven ovarian tumours showing allelic
losses in polymorphic markers (D3S1234, D3S1300, D3S4103) internal to
the FHlTgene. *, LOH; SS, not informative
Despite the high frequency of chromosome 3p aberrations
reported in ovarian malignancies, in the present study, we were able
to find allelic losses of the FHIT locus in 15% (8 of 54 cases) of
epithelial ovarian tumours and an aberrant FHITtranscript in only
4% (2 of 54 cases). These abnormal transcripts lack exon 5, which
contains in-frame ATG start codons, therefore the FHIT protein
encoded in these cases is unlikely to have functional properties.
In our study, to minimize contamination with nucleic acids
derived from non-neoplastic cells, which could lead to ambiguous
interpretation of data, only samples with a high proportion of
neoplastic cells were subjected to genetic analysis. However, we
cannot exclude the presence of a very small amount of normal
cells in our samples and therefore a possible underestimation of
allelic losses. On the other hand, in order to reduce the possibility
of an overestimation of allelic losses, we avoided a nested-PCR
strategy, which is more prone to false-positive results.
The inducible fragile site FRA3B contained within the FHIT
locus could make this region susceptible to some form ofneoplastic-
specific instability. Therefore, it has been argued that losses of
genetic material in the FHITlocus may be not related to tumorigen-
esis and that the FHITgene does not represent a true gene target for
cancer development (Thiagalingam et al, 1996). The absence of
LOH at the locus D3S1271, located outside the FHITgene, suggests
that the observed chromosomal losses are specific for the FHIT
gene. However, additional 3p markers have to be investigated to
delineate the extent ofchromosomal losses and to clarify this point.
Ovarian carcinomas are among the tumours with the highest
number of chromosomal aberrations. The low frequency of FHIT
alterations in such neoplasms strongly suggests that the FHIT
abnormalities do not occur randomly, as a consequence ofgenetic
instability, and they could exert a prominent aetiological role
in specific tumour types. In fact, the FHIT gene appears to be
involved particularly in tumours, such as small- and non-small-cell
lung cancers, directly associated with the effects of agents present
in tobacco smoke that interfere with DNA replication and repair.
On the other hand, ovarian carcinomas seem to be not related to
carcinogens, as suggested by recent observations indicating that
p53 mutations in ovarian cancer are mostly (72%) G:C to A:T
transitions occurring at CpG nucleotides (Shelling et al, 1995).
Such mutations are assumed to result from spontaneous deamina-
tion of 5-methylcytosine because of spontaneous errors in DNA
synthesis, rather than direct interaction with carcinogens.
However, the possibility that, in ovarian tumorigenesis, the
FHIT message may be affected at translational or post-transla-
tional levels can not be ruled out at present. Future studies on
FHIT protein expression will clarify this point.
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Finally, the majority of ovarian carcinomas are sporadic and
arise in peri- to post-menopausal age, while 10% of the cases are
hereditary and develop in young patients (Houlston et al, 1991).
To investigate the potential role of FHIT in sporadic and familiar
ovarian carcinomas, we included in this study 12 tumours devel-
oped in young women with a family history of breast/ovarian
cancer. In no case, did we find any alteration in the FHITlocus.
Although limited to a low number of tumours, our results
suggest that the FHIT gene is not involved in the development of
hereditary ovarian cancer.
In conclusion, our results indicate that FHIT plays a role in a
small proportion ofovarian carcinomas.
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